financetom
Business
financetom
/
Business
/
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
Jun 10, 2024 4:01 AM

06:44 AM EDT, 06/10/2024 (MT Newswires) -- Oculis Holding (OCS) said Monday it had detected favorable topline results from a phase 2b trial of licaminlimab for the treatment of patients with dry-eye disease.

The 122-patient study showed treatment effects "favoring" licaminlimab in multiple sign endpoints accepted by the US Food and Drug Administration.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CN Rail Up 0.1% In US Premarket As On Collective Agreement with IBEW
CN Rail Up 0.1% In US Premarket As On Collective Agreement with IBEW
Feb 18, 2025
06:35 AM EST, 02/18/2025 (MT Newswires) -- CN Rail (TSX: CNR and NYSE: CNI) was at last look up 0.1% in US premarket after it over the weekend announced that its new four-year tentative collective agreement with the International Brotherhood of Electric Workers (IBEW) was formally ratified by employees on Friday, February 14, 2025. The union represents approximately 750 Signals...
Oncolytics Biotech Gets Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Oncolytics Biotech Gets Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Feb 18, 2025
06:30 AM EST, 02/18/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) , a clinical-stage company specializing in immunotherapy for oncology, over the holiday weekend said it received a delinquency notification letter from the The Nasdaq Stock Market on February 13. A statement said the notice indicated the company was not, at that time, in compliance with the minimum bid...
Aurora Cannabis Eases Patient Access to Medical Cannabis Products in Australia, Files Short Form Base Shelf Prospectus
Aurora Cannabis Eases Patient Access to Medical Cannabis Products in Australia, Files Short Form Base Shelf Prospectus
Feb 18, 2025
06:32 AM EST, 02/18/2025 (MT Newswires) -- Aurora Cannabis ( ACB ) , a medical cannabis company, was at last look down 1.7% in US premarket trade Tuesday after over the holiday weekend sayin it had in conjunction with MedReleaf Australia recently removed the concession card requirement for patients to access medical cannabis products under the company's IndiMed brand. By...
Australia's Central Bank
Australia's Central Bank "Finals" Delivers A Pivito, With Caution, Says SocGen
Feb 18, 2025
06:34 AM EST, 02/18/2025 (MT Newswires) -- The Reserve Bank of Australia decided to lower the cash rate from 4.35% to 4.10% overnight Monday, as was suggested in the last policy meeting in December and supported by the significant easing of underlying inflation in Q4 2024, said Societe Generale. The policy statement did acknowledge that the inflation pressures were easing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved